1
|
Wagner R, Randolph JT, Patel SV, Nelson L, Matulenko MA, Keddy R, Pratt JK, Liu D, Krueger AC, Donner PL, Hutchinson DK, Flentge C, Betebenner D, Rockway T, Maring CJ, Ng TI, Krishnan P, Pilot-Matias T, Collins C, Panchal N, Reisch T, Dekhtyar T, Mondal R, Stolarik DF, Gao Y, Gao W, Beno DA, Kati WM. Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2018; 61:4052-4066. [PMID: 29653491 DOI: 10.1021/acs.jmedchem.8b00082] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Curative interferon and ribavirin sparing treatments for hepatitis C virus (HCV)-infected patients require a combination of mechanistically orthogonal direct acting antivirals. A shared component of these treatments is usually an HCV NS5A inhibitor. First generation FDA approved treatments, including the component NS5A inhibitors, do not exhibit equivalent efficacy against HCV virus genotypes 1-6. In particular, these first generation NS5A inhibitors tend to select for viral drug resistance. Ombitasvir is a first generation HCV NS5A inhibitor included as a key component of Viekira Pak for the treatment of patients with HCV genotype 1 infection. Since the launch of next generation HCV treatments, functional cure for genotype 1-6 HCV infections has been achieved, as well as shortened treatment duration across a wider spectrum of genotypes. In this paper, we show how we have modified the anchor, linker, and end-cap architecture of our NS5A inhibitor design template to discover a next generation NS5A inhibitor pibrentasvir (ABT-530), which exhibits potent inhibition of the replication of wild-type genotype 1-6 HCV replicons, as well as improved activity against replicon variants demonstrating resistance against first generation NS5A inhibitors.
Collapse
Affiliation(s)
- Rolf Wagner
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - John T Randolph
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Sachin V Patel
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Lissa Nelson
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Mark A Matulenko
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Ryan Keddy
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - John K Pratt
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Dachun Liu
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - A Chris Krueger
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Pamela L Donner
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Douglas K Hutchinson
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Charles Flentge
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - David Betebenner
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Todd Rockway
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Clarence J Maring
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Teresa I Ng
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Preethi Krishnan
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Tami Pilot-Matias
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Christine Collins
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Neeta Panchal
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Thomas Reisch
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Tatyana Dekhtyar
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Rubina Mondal
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - DeAnne F Stolarik
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Yi Gao
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Wenqing Gao
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - David A Beno
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Warren M Kati
- Global Pharmaceutical Research and Development , AbbVie , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| |
Collapse
|
2
|
Burbelo PD, Kovacs JA, Ching KH, Issa AT, Iadarola MJ, Murphy AA, Schlaak JF, Masur H, Polis MA, Kottilil S. Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients. J Infect Dis 2010; 202:894-8. [PMID: 20684729 DOI: 10.1086/655780] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
We quantified antibody responses to the hepatitis C virus (HCV) proteome that are associated with sustained virologic response (SVR) in human immunodeficiency virus (HIV)/HCV-coinfected patients treated with pegylated interferon and ribavirin. Analysis of pre- and posttreatment samples revealed significant decreases in the combined anti-core, anti-E1, and anti-NS4 HCV antibody titers in those with SVRs but not in those who experienced relapse or who did not respond. Furthermore, anti-HIV p24 antibody titers inversely correlated with treatment response. These results suggest that profiling anti-HCV antibody is useful for monitoring HCV therapy, especially in discriminating between those who experience relapse and those who have SVRs at 48 weeks.
Collapse
Affiliation(s)
- Peter D Burbelo
- Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Osinusi A, Rasimas JJ, Bishop R, Proschan M, McLaughlin M, Murphy A, Cortez KJ, Polis MA, Masur H, Rosenstein D, Kottilil S. HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. J Acquir Immune Defic Syndr 2010; 53:357-63. [PMID: 20101190 PMCID: PMC2852116 DOI: 10.1097/qai.0b013e3181c7a29d] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND This study aimed to assess the relationship between interferon (IFN)-related adverse effects and Hepatitis C virus (HCV) virologic response in HIV/HCV-coinfected individuals treated with pegylated interferon and ribavirin. METHODS We conducted 2 prospective, open-label trials treating HIV/HCV-coinfected individuals with pegylated interferon alpha-2b or alpha-2a and ribavirin for 48 weeks. Safety laboratories, HCV RNA, psychiatric, and ophthalmologic evaluations were performed at baseline and monthly until week 72. RESULTS Responders were defined as those with HCV RNA decline of > or = 2-log drop from baseline and nonresponders were those who did not. Remarkably, of the 27 patients (50%) who developed psychiatric toxicities, 26 patients were responders, although only 1 of 14 virologic nonresponders experienced psychiatric toxicity. Other adverse effects, such as anemia and ophthalmologic toxicities, were also more frequent in responders compared with nonresponders. Decline in CD4 T-cell counts strongly correlated with HCV viral decline. CONCLUSIONS Our study demonstrates coupling of antiviral effect and occurrence of adverse events in HIV/HCV-coinfected patients. These patients with IFN-related adverse effects need a multidisciplinary treatment approach, hence, they are more likely to achieve sustained virologic response. Future studies are needed to evaluate the factors that predict the development of IFN-alpha-dependent adverse events before therapy.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Henry Masur
- NCI, NIH, Bethesda, MD, CCMD, CC/NIH, Bethesda, MD
| | | | - Shyam Kottilil
- LIR, NIAID, NIH, Bethesda MD
- Correspondence to: Dr. Shyam Kottilil, Immunopathogenesis Section, Laboratory of Immunoregulation, NIAID, NIH, Bldg10, Rm.11N204, Bethesda, MD 20892 ()
| |
Collapse
|
4
|
Wagner R, Larson DP, Beno DWA, Bosse TD, Darbyshire JF, Gao Y, Gates BD, He W, Henry RF, Hernandez LE, Hutchinson DK, Jiang WW, Kati WM, Klein LL, Koev G, Kohlbrenner W, Krueger AC, Liu J, Liu Y, Long MA, Maring CJ, Masse SV, Middleton T, Montgomery DA, Pratt JK, Stuart P, Molla A, Kempf DJ. Inhibitors of Hepatitis C Virus Polymerase: Synthesis and Biological Characterization of Unsymmetrical Dialkyl-Hydroxynaphthalenoyl-benzothiadiazines. J Med Chem 2009; 52:1659-69. [DOI: 10.1021/jm8010965] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Rolf Wagner
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Daniel P. Larson
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - David W. A. Beno
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Todd D. Bosse
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - John F. Darbyshire
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Yi Gao
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Bradley D. Gates
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Wenping He
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Rodger F. Henry
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Lisa E. Hernandez
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | | | - Wen W. Jiang
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Warren M. Kati
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Larry L. Klein
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Gennadiy Koev
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - William Kohlbrenner
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - A. Chris Krueger
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Jinrong Liu
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Yaya Liu
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Michelle A. Long
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Clarence J. Maring
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Sherie V. Masse
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Tim Middleton
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Debra A. Montgomery
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - John K. Pratt
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Patricia Stuart
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Akhteruzzaman Molla
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| | - Dale J. Kempf
- Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064
| |
Collapse
|